Nine-gene pharmacogenomics profile service: The Mayo Clinic experience

  title={Nine-gene pharmacogenomics profile service: The Mayo Clinic experience},
  author={Eric T Matey and Ashley Kate Ragan and Lance J. Oyen and Carolyn Rohrer Vitek and Stacy L Aoudia and Ahmed K Ragab and Kelliann C. Fee-Schroeder and John L. Black and Ann M. Moyer and Wayne T. Nicholson and Sofia Shrestha and Tammy M. McAllister and Jason P. Sinnwell and Stephanie S. Faubion and Konstantinos N. Lazaridis},
  journal={The Pharmacogenomics Journal},
Purpose The Pharmacogenomics (PGx) Profile Service was a proof-of-concept project to implement PGx in patient care at Mayo Clinic. Methods Eighty-two healthy individuals aged 18 and older underwent genotyping of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, SLCO1B1, HLA-B*58:01 , and VKORC1 . A PGx pharmacist was involved in ordering, meeting with patients, interpreting, reviewing, and documenting results. Results Ninety three percent were CYP1A2 rapid metabolizers, 92% CYP3A4 normal… 

A Scoping Review of Attitudes and Experiences with Pharmacogenomic Testing among Patients and the General Public: Implications for Patient Counseling

A scoping review of published literature on patient experiences with PGx testing and a thematic analysis of qualitative and quantitative reports provide valuable context and potential areas of focus during patient counseling on PGx.



Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing

These data highlight three advantages of preemptive genotyping: the vast majority of patients carry at least one pharmacogenetic variant; data are available at the point of care; and there is a substantial reduction in testing burden compared with a reactive strategy.

Frequency of Undetected CYP2D6 Hybrid Genes in Clinical Samples: Impact on Phenotype Prediction

Phenotype before and after accurate genotyping was predicted using a method in clinical use and the presence of hybrid genes had no effect on the phenotype prediction of CYP2D6*4- and CYP1D7-2D 6*10-containing samples.

Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping

The results suggest that multiplexed, preemptive genotyping may represent an efficient alternative approach to current single‐use (“reactive”) methods and may also improve safety.

PharmGKB summary: very important pharmacogene information for CYP3A5.

The aim of a PharmGKB VIP summary is to provide a simple overview of a gene with respect to drug effects and to highlight the gaps in knowledge where further study would aid the field.

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

The purpose of this article is to assist in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2–3, should genotype results be available to the clinician.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

The multivariate regression model including the variables of age, CYP2C9 and VKORC1 genotype, and height produced the best model for estimating warfarin dose (R2 = 55%).